



המינהל לטכנולוגיות רפואיות ותשתיות
אגף הרוקחות | המכון לביקורת ותקנים של חומרי רפואה
The Institute for Standardization and Control of Pharmaceuticals

משרד
הבריאות
לחיים בריאים יותר

אישור יצרן / יבואן תכשירים רפואיים MANUFACTURER'S / IMPORTER'S AUTHORIZATION

Authorization number	מספר האישור
MIA 230/2024/C	
Name of authorization holder	שם בעל האישור
Isotopia Molecular Imaging Ltd.	איזוטופיה מולקולר אימג'ינג בע"מ
Address of site	כתובת האתר
Soreq Nuclear Research Center, Yavne, 81800, Israel	המרכז למחקר גרעיני שורק, יבנה 81800
Legally registered address of authorization holder	כתובת בעל האישור
As written above	ברשום לעיל
Scope of authorization and dosage forms	תחומי האישור וצורות המינון
See Annexes 1, 2	ראה נספחים 1, 2
Legal basis of authorization	הבסיס החוקי לאישור
Pharmacist Regulations [Good Manufacturing Practice] 2008	תקנות הרוקחים [תנאי ייצור נאותים] תשס"ח
Responsible officer of Israeli Ministry Of Health granting the authorization	בעל התפקיד ברשות האחראי למתן האישור
Michael Carmi, Pharmacist GMP inspector	מיכאל כרמי, רוקח יכז ארצי בקרת מפעלים
Signature, stamp and date	חתימה, חותמת ותאריך
Email: michael.carmi@moh.gov.il Phone: office 972 -2-6551795 cell 972-50-6242452	 מיכאל כרמי ע. מפקח ארצי תנאי ייצור נאות 07-07-2024

MIA 230/2024/C

page 1 of 4



SCOPE OF AUTHORIZATION : ANNEX 1 – MEDICINAL PRODUCTS

Name and address of the site **Isotopia Molecular Imaging Ltd.**
Soreq Nuclear Research Center, Yavne, 81800, Israel

<input checked="" type="checkbox"/>	Human Medicinal Products
AUTHORIZED OPERATIONS	
<input checked="" type="checkbox"/>	Manufacturing Operations (according to part 1)
Part 1 - MANUFACTURING OPERATIONS	
1.1	Sterile products
	1.1.1 Aseptically prepared 1.1.1.2 Lyophilizates 1.1.1.4 Small volume liquids 1.1.1.6. Other aseptically prepared products
	1.1.2 Terminally sterilized 1.1.2.3 Small volume liquids
	1.1.3 Batch certification
1.4	Other products or manufacturing activity
	1.4.1 Manufacture of: 1.4.1.3 Other: Lyophilization of active substances (<i>for other parties</i>)
1.5	Packaging
	1.5.1 Primary packing
	1.5.2 Secondary packing
1.6	Quality control testing
	1.6.1 Microbiological: sterility
	1.6.2 Microbiological: non-sterility
	1.6.3 Chemical/Physical
	1.6.4 Biological

07-07-2024

מיכאל כרמי
ע. מפקח ארצי
תנאי יצור נאותים

MINISTRY OF HEALTH JERUSALEM
GOV. INSTITUTE
FOR
CONTROL AND STANDARD
OF
PHARMACEUTICALS
משרד הבריאות



Any restrictions or clarifying remarks related to the scope of the medicinal products

The main activity on site is the manufacture of sterile medicinal products, by aseptic processing and terminal sterilization.

The plant is also authorized to perform lyophilization of active substance and inert matrixes (vehicles) as a contract agent of other parties.



07-07-2024

מיכאל כרמי
ע. מפקח ארצי
תנאי יצור נאותים



SCOPE OF AUTHORIZATION : ANNEX 2 - INVESTIGATIONAL MEDICINAL PRODUCTS

Name and address of the site **Isotopia Molecular Imaging Ltd.**
Soreq Nuclear Research Center, Yavne, 81800, Israel

☒ Human Investigational Medicinal Products

AUTHORIZED OPERATIONS

☒ Manufacturing Operations (according to part 1)

1.

1. MANUFACTURING OPERATIONS OF INVESTIGATIONAL PRODUCTS

1.1 Sterile products

1.1.1 Aseptically prepared

1.1.1.2 Lyophilizates

1.1.1.4 Small volume liquids

1.1.3 Batch certification

Any restrictions or clarifying remarks related to the scope of the investigational products

This authorization pertains to the following IMPs (both of them are for Phase III clinical trials):

- *Sterile Hydrogel for UGN-102. This product is manufactured under a contractual agreement with Urogen Pharma Ltd*
- *ELGN-2112, oral formulation of recombinant human insulin under clinical development to stimulate the development of extremely low gestational age newborns (born more than 3 months before term). This product is manufactured under a contractual agreement with Elgan Pharma Ltd.*

Investigational products are not included in the ACAA between the EU and Israel

IMPS for phase III clinical trials are periodically inspected under the inspection programme, IMPs for phases I, II, are inspected under regulatory risk management / per requests



מיכאל כרמי
ע. מפקח ארצי
תנאי יצור נאותים

MIA 230/2024/C

page 4 of 4

תל- 7 07